The European Medicines Agency (EALS) has approved Gilead Sciences Inc’s drug, remdesivir, for use in COVID-19 patients across the continent, Reuters reported.

According to the EALS, its human medicines committee (CHMP) recommended the drug to be prescribed to adults and adolescents from 12 years with pneumonia who require supplemental oxygen.

Dutch experts expect the European Commission to approve the drug next week.